These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 26456124)
1. Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Varmeh S; Vanden Borre P; Gunda V; Brauner E; Holm T; Wang Y; Sadreyev RI; Parangi S Surgery; 2016 Jan; 159(1):152-62. PubMed ID: 26456124 [TBL] [Abstract][Full Text] [Related]
2. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Nucera C; Nehs MA; Nagarkatti SS; Sadow PM; Mekel M; Fischer AH; Lin PS; Bollag GE; Lawler J; Hodin RA; Parangi S Oncologist; 2011; 16(3):296-309. PubMed ID: 21355020 [TBL] [Abstract][Full Text] [Related]
3. Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation. Byeon HK; Na HJ; Yang YJ; Ko S; Yoon SO; Ku M; Yang J; Kim JW; Ban MJ; Kim JH; Kim DH; Kim JM; Choi EC; Kim CH; Yoon JH; Koh YW Oncotarget; 2017 Jan; 8(1):596-609. PubMed ID: 27880942 [TBL] [Abstract][Full Text] [Related]
4. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. Salerno P; De Falco V; Tamburrino A; Nappi TC; Vecchio G; Schweppe RE; Bollag G; Santoro M; Salvatore G J Clin Endocrinol Metab; 2010 Jan; 95(1):450-5. PubMed ID: 19880792 [TBL] [Abstract][Full Text] [Related]
5. c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition. Byeon HK; Na HJ; Yang YJ; Kwon HJ; Chang JW; Ban MJ; Kim WS; Shin DY; Lee EJ; Koh YW; Yoon JH; Choi EC Mol Carcinog; 2016 Nov; 55(11):1678-1687. PubMed ID: 26456083 [TBL] [Abstract][Full Text] [Related]
6. Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways. Gunda V; Bucur O; Varnau J; Vanden Borre P; Bernasconi MJ; Khosravi-Far R; Parangi S Cell Death Dis; 2014 Mar; 5(3):e1104. PubMed ID: 24603332 [TBL] [Abstract][Full Text] [Related]
7. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation. Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953 [TBL] [Abstract][Full Text] [Related]
8. The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors. Coperchini F; Croce L; Denegri M; Awwad O; Ngnitejeu ST; Muzza M; Capelli V; Latrofa F; Persani L; Chiovato L; Rotondi M Sci Rep; 2019 Mar; 9(1):4390. PubMed ID: 30867499 [TBL] [Abstract][Full Text] [Related]
9. miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment. Liu S; Tetzlaff MT; Wang T; Yang R; Xie L; Zhang G; Krepler C; Xiao M; Beqiri M; Xu W; Karakousis G; Schuchter L; Amaravadi RK; Xu W; Wei Z; Herlyn M; Yao Y; Zhang L; Wang Y; Zhang L; Xu X Pigment Cell Melanoma Res; 2015 Jul; 28(4):431-41. PubMed ID: 25903073 [TBL] [Abstract][Full Text] [Related]
10. Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer. Gunda V; Cogdill AP; Bernasconi MJ; Wargo JA; Parangi S Surgery; 2013 Dec; 154(6):1456-62; discussion 1462. PubMed ID: 24238058 [TBL] [Abstract][Full Text] [Related]
11. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572 [TBL] [Abstract][Full Text] [Related]
12. mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib. Hanly EK; Bednarczyk RB; Tuli NY; Moscatello AL; Halicka HD; Li J; Geliebter J; Darzynkiewicz Z; Tiwari RK Oncotarget; 2015 Nov; 6(37):39702-13. PubMed ID: 26284586 [TBL] [Abstract][Full Text] [Related]
13. Targeting NG2 relieves the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors. Sui F; Wang G; Liu J; Yuan M; Chen P; Yao Y; Zhang S; Ji M; Hou P Cell Mol Life Sci; 2024 May; 81(1):238. PubMed ID: 38795180 [TBL] [Abstract][Full Text] [Related]
14. Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma. Limberg J; Egan CE; Gray KD; Singh M; Loewenstein Z; Yang Y; Riascos MC; Al Asadi H; Safe P; El Eshaky S; Liang H; Ullmann TM; Wang W; Li W; Zhang T; Xiang J; Stefanova D; Jin MM; Zarnegar R; Fahey TJ; Min IM Mol Cancer Res; 2023 May; 21(5):397-410. PubMed ID: 36790391 [TBL] [Abstract][Full Text] [Related]
15. Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma. Capaldo BJ; Roller D; Axelrod MJ; Koeppel AF; Petricoin EF; Slingluff CL; Weber MJ; Mackey AJ; Gioeli D; Bekiranov S PLoS One; 2015; 10(9):e0138210. PubMed ID: 26405815 [TBL] [Abstract][Full Text] [Related]
17. Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. Nehs MA; Nucera C; Nagarkatti SS; Sadow PM; Morales-Garcia D; Hodin RA; Parangi S Endocrinology; 2012 Feb; 153(2):985-94. PubMed ID: 22202162 [TBL] [Abstract][Full Text] [Related]
18. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Jiang CC; Lai F; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD Clin Cancer Res; 2011 Feb; 17(4):721-30. PubMed ID: 21088259 [TBL] [Abstract][Full Text] [Related]
19. Differential effects of MAPK pathway inhibitors on migration and invasiveness of BRAF(V600E) mutant thyroid cancer cells in 2D and 3D culture. Ingeson-Carlsson C; Martinez-Monleon A; Nilsson M Exp Cell Res; 2015 Nov; 338(2):127-35. PubMed ID: 26384551 [TBL] [Abstract][Full Text] [Related]